Spexis AG Logo

Spexis AG

Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.

SPEX | SW

Overview

Corporate Details

ISIN(s):
CH0106213793
LEI:
391200S8HJE1I96FIG04
Country:
Switzerland
Address:
Hegenheimermattweg 125, 4123 Allschwil
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Spexis AG is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics for rare diseases and oncology. The company leverages its proprietary technology platform centered on macrocyclic molecules to create novel treatments. Its development pipeline primarily targets indications in rare, chronic respiratory diseases, such as cystic fibrosis, as well as heme-oncology. Formerly known as Polyphor AG, Spexis is advancing its portfolio to address significant unmet medical needs in its core therapeutic areas.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-05 07:15
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
English 9.3 KB
2024-11-05 01:00
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
English 7.7 KB
2024-07-29 07:15
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
English 8.6 KB
2024-07-29 02:00
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
English 6.9 KB
2024-07-22 07:15
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
English 10.8 KB
2024-07-22 02:00
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
English 9.1 KB
2024-07-08 07:15
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBioti…
English 10.0 KB
2024-07-08 02:00
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiot…
English 8.4 KB
2024-06-04 20:00
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
English 8.0 KB
2024-06-04 02:00
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
English 6.4 KB
2024-05-31 22:00
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
English 19.4 KB
2024-05-31 02:00
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
English 16.6 KB
2024-04-30 20:30
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
English 9.8 KB
2024-04-30 02:00
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
English 8.2 KB
2024-04-17 07:15
Regulatory News Service
Spexis announces extension of moratorium, receipt of an additional payment rela…
English 13.8 KB

Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Spexis AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Spexis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-21 N/A Executive member Other None N/A

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.